Highlights

  • Telix Pharmaceuticals reported Q2 2026 group Revenue of US$247 million, up 21% year-on-year.
  • The company expects 2026 revenue plus other income to exceed US$1 billion.
  • Precision Medicine revenue reached US$202 million in the quarter, supported by prostate cancer imaging products.
  • Telix progressed multiple therapeutic programs including TLX591-Tx, TLX597-Tx, TLX250-Tx and TLX101-Tx.

Telix Pharmaceuticals (ASX:TLX) has reported its strongest quarterly revenue performance to date and reaffirmed that combined 2026 revenue and other income is expected to exceed US$1 billion.

The 20 July 2026 update showed group revenue of US$247 million for Q2 2026, representing a 7% increase compared with the prior quarter and 21% growth compared with the same period last year.

The company's Precision Medicine imaging division continues to contribute the majority of current revenue, while therapeutic pipeline development and a new collaboration with Regeneron Pharmaceuticals expand Telix's longer-term growth strategy.

What Was Announced?

Telix reported Q2 2026 group revenue of US$247 million, with its Precision Medicine segment contributing US$202 million.

Precision Medicine revenue increased 9% quarter-on-quarter and 30% year-on-year, supported by prostate cancer imaging products.

The company's other reporting segment contributed US$45 million during the quarter.

Telix stated that full-year 2026 revenue is tracking toward the upper end of its previous guidance range of US$950–970 million.

In addition, the company expects a US$40 million non-refundable payment from Regeneron Pharmaceuticals under a strategic collaboration focused on developing and commercialising next-generation radiopharmaceutical therapies, initially targeting lung cancer.

Combining revenue expectations and the Regeneron payment, Telix expects total 2026 revenue plus other income to exceed US$1 billion.

The company also provided updates across its clinical pipeline. The FDA cleared Part 2 of the ProstACT Global Phase 3 trial for TLX591-Tx, while Telix completed enrolment in the OPTIMAL-PSMA study for TLX597-Tx and commenced the OPTIMAL-e Phase 2 study.

The company also dosed the first patient in the LUTEON kidney cancer trial for TLX250-Tx and enrolled the first cohort in the IPAX BrIGHT trial for TLX101-Tx in recurrent glioblastoma.

Why This Matters

For Telix (ASX:TLX), reaching a scale of more than US$1 billion in annual revenue and other income expectations reflects the transition from an emerging radiopharmaceutical developer toward a commercial-stage business.

The current revenue base remains centred on Precision Medicine products including Illuccix and Gozellix, which continue to support growth in prostate cancer imaging.

The Regeneron collaboration adds another development pathway by combining Telix's radiopharmaceutical capabilities with external antibody technology.

However, the therapeutic pipeline remains in clinical development, meaning future Diversification beyond imaging depends on successful trial outcomes and regulatory approvals.

Company Background

Telix Pharmaceuticals (ASX:TLX) is a biopharmaceutical company focused on radiopharmaceuticals, which combine targeting molecules with radioactive isotopes for diagnostic imaging and targeted therapy.

Its commercial portfolio includes Illuccix and Gozellix, prostate cancer imaging products used across multiple markets.

The company is also progressing imaging products including Pixclara, Pixlumi and Zircaix.

Beyond imaging, Telix's therapeutic pipeline includes TLX591-Tx and TLX597-Tx for prostate cancer, TLX250-Tx for kidney cancer and TLX101-Tx for brain cancer.

The Regeneron collaboration expands the company's focus into lung cancer applications.

Financial Position

Telix did not disclose its specific cash and cash equivalents balance as at 30 June 2026 in the announcement reviewed for this article.

The company has guided Research and Development expenditure of US$230–270 million for 2026 as it continues Investment across multiple therapeutic programs.

Further Balance Sheet details are expected through the company's upcoming Appendix 4D half-year report.

What Comes Next?

The next key developments for Telix (ASX:TLX) include progress across multiple clinical programs.

Investors will monitor Part 2 of the ProstACT Global Phase 3 trial for TLX591-Tx, further enrolment and data from the OPTIMAL-e Phase 2 study, and continued dosing progress in the LUTEON and IPAX BrIGHT trials.

The Regeneron collaboration will also be monitored as it moves toward development milestones in lung cancer.

The company has not disclosed specific completion dates or regulatory filing timelines for these programs.

Risks

Telix (ASX:TLX) remains exposed to clinical, regulatory and commercial risks across its expanding pipeline. The target of more than US$1 billion in 2026 revenue and other income depends on continued imaging product growth and receipt of expected collaboration payments. Therapeutic programs remain subject to trial outcomes and regulatory review. Radiopharmaceutical Manufacturing and Supply chains require specialised infrastructure due to isotope characteristics. Increasing research and development expenditure may also affect margins if revenue growth does not continue.

Investor Takeaway

Telix has reported another quarter of revenue growth, supported by its imaging Business and continued advancement of its therapeutic pipeline.

The expectation of more than US$1 billion in 2026 revenue and other income represents a scale milestone for Telix (ASX:TLX), while the Regeneron collaboration adds another development opportunity.

The key longer-term question remains whether therapeutic programs can successfully progress through clinical development and diversify revenue beyond the current imaging-focused commercial base.